Lv1
36 积分 2024-06-08 加入
A Review of Immunotherapy for Head and Neck Cancer
3天前
已完结
Neoadjuvant immune checkpoint blockade enhances local and systemic tumor immunity in head and neck cancer
3天前
已完结
Data from A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers
7天前
已关闭
Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit
7天前
已完结
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial
7天前
已完结
Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization
20天前
已完结
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
28天前
已完结
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
28天前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
28天前
已完结
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
28天前
已完结
皖公网安备34019202002308
